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Abstract
The Conference on Asian Trends in Prostate Cancer Hormone Therapy is an annual forum for Asian urologists
now in its 5th year. The 2006 conference, held in Bali, Indonesia, was attended by 27 leading urologic oncologists
from China, Indonesia, Japan, Korea, Singapore, and Taiwan and featured a packed program of presentations and
discussions on a wide range of topics such as relationships among clinicians and the newly opened Asia Regional
Office for Cancer Control of the International Union Against Cancer (UICC), detection rates of prostate cancer by
biopsy in each of the 6 Asian countries, and favored treatment modalities for hormone-refractory prostate cancer
(HRPC) in each country.
The first session of the conference kicked off with a keynote lecture entitled “Activities of the UICC ARO”.
UICC’s new office will be the nerve center for its activities in the Asia region. Along with the Asian Pacific Organization
for Cancer Prevention (APOCP), UICC aims to shift the focus of attention to cancer control. As such APOCP's
long-running publication the APJCP is to be re-launched as the Asian Pacific Journal of Cancer Control.  Although
UICC is primarily concerned with cancer, several risk factors for cancer are common also to other non-communicable
diseases such as diabetes and heart disease, and an important strategy is to implement measures to control these
various pathologic conditions as a whole. Apart from contributing to an Asian prostate cancer registry the UICC-
ARO will provide training courses, working groups, and assistance in collecting and processing data.
The keynote lecture was followed by a roundtable discussion on possible ways in which clinicians from each
Asian country can work with UICC.  A number of suggestions were put forth including better registration,
epidemiology research, possible implementation of UICC prostate cancer guidelines, early detection and screening,
and roles of diet and phytotherapy. The underlying reasons for the large but dwindling difference in incidence rates
of prostate cancer in various regions of Asia should be studied while the opportunity lasts.
Session 2 was devoted to 6 presentations on detection rates by biopsy in each country. Although biopsy is the
gold standard for detecting prostate cancer in most areas, indications for conducting biopsy are different in each
country. For example, in Indonesia doctors may use PSAD 0.15 as the cutoff level. TRUS-guided biopsy is most
widely used in Asian countries. Traditional sextant biopsy is often performed, although multiple-core biopsy is
commonly available and associated with better detection rates, especially in men with large prostate volume. Positive
DRE, high PSA, and older age were identified as factors associated with high biopsy detection rate, although elevated
PSA has limited specificity. First biopsy in men with elevated PSA had a positive detection rate of approximately
30% in all countries. Community-based screening in some countries has an overall detection rate of approximately
1%.
The favorable treatment modality for HRPC was the subject of the final session. First priority for doctors in all
6 countries is to maintain serum testosterone at castration level. Many therapeutic options are available, from
cytotoxic drugs to traditional herbal medicines  Chemotherapeutic agents such as estramustine, docetaxel,
cyclophosphamide, and mitoxantrone are often given to patients with HRPC although not all are available in every
country. Prednisone and dexamethasone are used for secondary hormonal therapy.  External beam radiotherapy,
radioisotopic drugs such as strontium 89, and bisphosphonates are common choices to control bone pain.
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Introduction
The 5thConference on Asian Trends in Prostate Cancer
Hormone Therapy was held at the Sheraton Laguna Nusa
Dua, Bali, Indonesia, on Sunday, August 27, 2006. Twenty-
seven leading urologic oncologists from 6 Asian countries
(China, Indonesia, Japan, Korea, Singapore, and Taiwan)
converged at the venue to listen to a keynote lecture titled
“Activities of the International Union Against Cancer
(UICC) Asian Division” presented by Malcolm Moore and
to engage in a program of roundtable discussions on topics
of possible future relationships among prostate cancer
clinicians and the UICC in Asia, detection rates of prostate
cancer by biopsy in each country, and favored treatment
modalities for hormone-refractory prostate cancer (HRPC)
in each country. The principal themes of the 2006 conference
were expressed by conference chair Hideyuki Akaza (Japan)
who in his opening remarks stated that the society is ready
to take the first steps towards instigating clinical trials in
the region. Ethnicity among Asian peoples exhibits more
similarity than it does with western peoples, he added.
Although in the field of prostate cancer currently 90% of
original published research derives from researchers in the
USA and Europe, it seems that more effort should be focused
on gathering evidence in Asian prostate cancer patients.
Professor Akaza welcomed distinguished guest speaker Dr
Moore and congratulated him on his efforts in founding the
UICC Asia Regional Office, which is due to open in
Bangkok, Thailand, in 2006.
     Following these opening remarks, Rainy Umbas (Jakarta,
Indonesia) delivered a welcome address and expressed his
wishes that the day’s discussions may prove fruitful and
contribute to greater improvements in the management of
prostate cancer.
I. Session 1: Activities of the Conference on
Asian Trends in Prostate Cancer Hormone
Therapy (chaired by Hideyuki Akaza and
Malcolm Moore)
1. Keynote Lecture: Activities of the UICC Asian Division,
Malcolm Moore
After many years of continuous activity, the UICC
Japanese committee decided to support an office for the Asia
region as a whole. Over the last 5–6 years, the UICC has
been involved with many different researchers and clinicians
all over Asia, in particular in connection with its sister
organization, the nonprofit concern Asian Pacific
Organization for Cancer Prevention (APOCP) and its
quarterly publication the Asian Pacific Journal of Cancer
Prevention (APJCP).
     With the opening of the UICC Asia regional office in
2006, the intention is for the APOCP to expand its activities
to include cancer control. To this effect, the journal will be
renamed the Journal of Cancer Control. The UICC Asia
regional office will be responsible for the journal's
publication and for preparing a number of meetings during
the year.
     Cancer prevention and cancer control have a long and
international history that can be traced back to Ramazzini's
observations of breast cancer occurring in Italian nuns in
1700 through to Sugimura’s recent work on heterocyclic
amines and cancer in Japan (Table 1). This historic
cooperative effort is certainly set to feature increasingly
more Asian contributions in future. There have also been a
significant number of national cancer associations starting
with the Anti-cancer League in France in 1893 to the present
situation wherein almost all Asian countries have their own
anticancer association or cancer societies, many of which
are members of UICC or the Asian Pacific Federation of
Organizations for Cancer Control (APFOCC). Hence there
is a proliferation of national organizations brought together
under the aegis of larger international organizations, not only
UICC (established in 1933) but also the World Health
Organization (WHO; founded 1948), International Agency
for Research on Cancer (IARC; 1965), and so on, each with
its own calendar of regular meetings and events. Last but
not least, there is the International Association of Cancer
Registries.
     Although the UICC World Cancer Congress is presented
as a global platform for cancer research, statistics show that
Asia is severely underrepresented in terms of speakers at
the conference: recently of 39 plenary speakers 18 were
North American, 10 European, and only 2 were from Asia
(one each from Mainland China and Hong Kong). To put
this in perspective, there were 250 times as many Australians
as there were Asians in terms of their relative populations
(4 speakers from a total population of 24 million versus 2
representing 4040 million, respectively). Therefore the
utmost should be done to increase Asian presence in the
fight against cancer. To this effect it has been proposed that
international organizations such as UICC, WHO, and IARC
will focus more attention on Asia Pacific by bringing
together APOCP (and APJCP), APFOCC, and WHO’s
Regional Offices for South East Asia (SEARO) and Western
Pacific (WPRO) so as to work more closely together in Asia.
Although the UICC is primarily concerned with cancer,
several risk factors for cancer especially adenocarcinoma
are common also to diabetes and heart disease; therefore it
is reasonable for cancer control organizations to think in
terms of overall noncommunicable disease (NCD) control.
In Japan for example cancer-related mortality is highly
prevalent in males and females at approximately 30% of all
deaths, with cerebrovascular disease the second-most
common cause of death from NCD. Regarding prostate
cancer, the incidence rate is very high in Australia and New
Table 1. Historic Findings in Cancer Causality
Year Scientist(s) Findings
1700 B Ramazzini Occupation, breast cancer in nuns
1761 J Hill Snuff tobacco and nasal polyps
1775 P Pott Chimney sweeps and scrotal cancer
1851 T H Bilharz Parasites and cancer
1871 R Virchow Irritation theory
1879 F H Harting/W Hess Lung cancer among miners
1895 L Rehn Aniline dyes and bladder cancer
1915 K Yamagiwa/ K Ichikawa  Tar-induced skin cancer
1920 R Sasaki Azodyes and liver cancer
1995 T Sugimura Heterocyclic amines and cancer
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Zealand and quite high in the Philippines, Japan, and
Malaysia and the problem is expected to increase in the
future. Focusing on other etiologically linked diseases,
cerebrovascular and ischemic heart diseases are following
a similar pattern of increased prevalence, as is the pattern
of diabetes prevalence, with Japan having the worst problem,
although up-to-date data are insufficient in many countries
in the Asian region. Better registration of disease
epidemiology is required. In any case, over the next 20 years
an explosion in the number of Asian people who are obese
with diabetes, with a concomitant increase in breast cancer
and possibly prostate cancer along with many of the other
adenocarcinomas, is foreseen. Therefore agencies such as
UICC will be trying to bring together researchers and
clinicians operating in different disease areas so as to reduce
risk factors and promote beneficial factors for cancer,
cardiovascular diseases, and diabetes, which considerably
overlap.
     Figure 1 shows a triad for determinants of our health
and illustrates a schema for input required from various
health and environmental professionals and organizations
for the promotion of NCD control. Basically, it is envisaged
that the pharmaceutical industry, government policymakers,
health professionals such as surgeons and clinicians, cancer
registries, epidemiologists, toxicological pathologists, and
screening centers will work together under the auspices of
organizations such as APOCP to fight cancer and other
NCDs. The four main areas of activity within the UICC
Asia regional office will be disease diagnosis and
registration, risk factor and protective factor identification,
practical primary and secondary prevention, and clinical
treatment and palliative medicine. Our approach to the first
of these aims, diagnosis and registration, will be to set up
an Asian network for cancer registration similar to the
European and North American models (European Network
of Cancer Registries and North American Association of
Central Cancer Registries, respectively) to collate up-to-
date information on cancer incidence, prevalence, and
mortality so as to enable us to devise plans to tackle the
disease. Although there are several extant cancer registries
at the local level in Asia, these only cover small sections of
the population and there are many countries for which
registries are not established. Therefore another of the aims
of the UICC Asian network will be to provide training
courses, working groups, and assistance in collecting and
processing data.
Although it is known that the majority of prostate cancers
arise in the peripheral zone with high-grade prostate
intraepithelial neoplasia (PIN) or atypical small acinar
proliferation (ASAP), there are many aspects of this disease
that are less clear. For example, what is the involvement of
benign prostate hyperplasia? What are the differences
between cancers that arise in different zones of the prostate
gland? These are examples of areas within the pathology
field that still require a great deal of exploration, especially
since most of the data that are available derive from the
USA and Europe. Comparative Asian data are severely
lacking. For this reason one of the aims of UICC Asian
division is to introduce a hospital-based registration system
to collect urgently needed data.
     The second major aim of the UICC in Asia is to identify
risk factors and beneficial factors as determined by tissue
physiology (Figure 2). In the peripheral, transitional, and
central zones of the prostate for example several factors
have differing effects on carcinogenesis, including
inflammation, sexually transmitted diseases, exposure to
carcinogens, metabolizing enzymes, and dietary pressure,
physiological pressure, and hormonal milieu must be taken
into consideration. PSA production and entry into the
bloodstream need better understanding, as do the influences
of ejaculation and zinc metabolism and the role of exercise.
     Primary and secondary prevention of prostate cancer
refers to prevention strategies in men who do not have any
evidence of the disease and in those who have screened
positively for precancerous lesions, respectively. There are
many different modalities that can be explored in primary
and secondary prevention, but the most effective means of
prostate cancer prevention are not well understood.
     Finally, the UICC Asian office aims to become involved
in the area of cancer clinical intervention. This includes
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screening and diagnostics, hormone therapy, surgery,
radiotherapy and chemotherapy, and palliative care. It has
been proposed that introducing a hospital-based clinical
registration system across Asia using a standardized protocol
could be a very useful tool with which to conduct
investigations of clinical interventions by enabling us to
obtain easily comparable data. With this tool researchers
can look at screening, biopsy, treatment, and outcomes.
Furthermore, a comprehensive explanatory document
published in English, Chinese, Japanese, Korean,
Indonesian, Malaysian, and so on could enable us to
standardize and very quickly produce a large database of
information on risk factors such as diet, exercise, supplement
intake, body size, hormone level, and morphology of the
prostate. For screening, many PSA parameters and
complicating factors are vitally needed data, as is evidence
for biopsy methodology, the number of cores required, and
pathological diagnosis of lesions observed. Treatment
strategies must be determined by decision making at the
individual patient level, including quality of life, watchful
waiting, and the various different treatment modalities
including hormonal, surgical, and radiation therapy,
chemotherapy alone and in combination, and so on, which
are all questions that require answers in the Asian context
since to date there have been very few papers published
from this part of the world (see Cheng et al., 2006).
The role of UICC in Asia can be summarized as to form
a “cooperation triad” of policy, information, and intervention
in the region. Policy is dictated by governments and to a
certain extent by WHO; the ecological environment is
regulated by laws and the application of taxation, and the
environment in turn impacts on what diseases the people
develop. Hence policy is very important. Information is
dependent on our understanding of incidence, prevalence,
and mortality rates of diseases such as prostate cancer. This
helps us to identify risk and beneficial factors, and with this
knowledge we can assess at the local environmental level
socioeconomic influences. Gathering this information is the
role of research institutions and organizations such as
national cancer centers, local hospitals, universities, and
research groups. Finally, evidence-based information can
be used for the purpose of intervention among local
populations by promoting education and awareness,
supporting community-based projects, and encouraging
hospital-based clinical cooperation.
     The UICC Asia regional office at first will be a small
office in Bangkok. It will have a library open to visitors,
but most importantly the office will form a physical base
for UICC operations. The office will run a web site for free
communication and downloads such as guidebooks and
other cancer information in several languages. The APJCP
journal is available on PubMed and likewise all PDF files
are available as free downloads. The UICC Asia regional
office will provide several training courses and books
including an Asian handbook for cancer prevention probably
within 2007. The office will also act as a research
collaboration center. A number of meetings are also planned,
or have been held, for example a breast cancer meeting in
November 2006; the UICC strongly promotes the idea of
having more cancer congresses and specialist meetings in
the Asia region.
2. Roundtable Discussion: The Possible Future Relationship
with the UICC in the Field of Prostate Cancer
The first session concluded with a roundtable discussion
in which the chairpersons were joined by Shujie Xia (China),
Rainy Umbas (Indonesia), Masaru Murai (Japan), Choung-
Soo Kim (Korea), Han Yong Choi (Korea), Christopher
Cheng (Singapore), and Chi-Rei Yang (Taiwan), who each
presented brief comments on possible ways in which their
countries might benefit from working with the UICC in Asia.
     Doctor Xia began the proceedings by stating that in China
the Chinese Urological Association (CUA) has a number
of different specialty groups such as uro-oncology,
endourology, urinary stone, urodynamics, andrology, and
transplantation. Many guidelines have been issued by CUA
including guidelines for prostate cancer, BPH, urinary stone,
overactive bladder, and prostatitis. However, the incidence
of prostate cancer especially is fast increasing in China, so
there is much room for cooperation with UICC, especially
in the immediate areas of epidemiological research,
differences in therapeutic approaches in each region such
as pharmacologic or surgical castration, and possible
implementation of a UICC prostate cancer guideline.
Furthermore, the presence of UICC in Asia brings promise
of the exciting possibility of conducting prospective multi-
country clinical trials in the region.
     Following this, Dr Umbas made a short presentation
focusing on the clinical situation of prostate cancer in
Indonesia. According to the government, prostate cancer is
included among the 10 most common malignancies in men,
although whether this is accurate is obscure because the
last survey was conducted a decade ago in 1996. In fact, the
incidence rate of prostate cancer in Indonesia is unknown.
At the University of Indonesia Cipto Mangunkusumo
Hospital most (75%) prostate cancer patients present with
stage III–IV disease. Over the last 10 years, the number of
patients referred to the hospital for prostate cancer treatment
has trebled. Hence the most urgent need in Indonesia is to
get information on prostate cancer prevalence. It is hoped
that with the aid of UICC a national cancer registry can be
developed in Indonesia similar to those of Japan and Korea.
In addition, in cooperation with the Indonesian Cancer
Foundation and Indonesian Urological Association, there
is a need for a national program of early detection and
screening because currently this varies widely depending
on the geographical area and at each hospital. An
epidemiological study especially in rural areas could provide
valuable data since in western countries where there is a
very high incidence of prostate cancer it is difficult to
discover factors that could prevent the disease, whereas if
in some parts of Indonesia the prevalence is very low this
would be of interest. This approach has already been started
in China in collaboration with some European countries and
research centers that are looking into why prostate cancer
is so uncommon in China. Lastly, Indonesian researchers
are very interested in conducting or collaborating in research
on the roles of diet and phytotherapy, especially the latter
which is very popular in Asian countries on the whole: the
first medication that many Asian patients will take is a herb
even before going to see a doctor.
     Next, Professor Murai made some comments on the
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natural history and epidemiology of prostate cancer.
Although in Asia the incidence of prostate cancer is still
low, it is rising sharply. In Japan, there is still no complete
national database set up as yet but several registration
systems exist and also some clinical studies have been
conducted. From 2001, the Japanese Urological Association
(JUS) started a computer-based registry of prostate cancer
patients and the first report, which appeared in the December
2005 issue of IJUA, presented data on a total of 4,529
patients at 173 institutions. In addition, the ongoing JCAP
Study of endocrine therapy with or without adjuvant
treatment has so far accrued approximately 9000 prostate
cancer patients annually. Another study of brachytherapy
startedin 2005 and has enrolled 3000 patients. There are
1200 educational hospitals in Japan and most surgical
procedures were conducted therein: the number of radical
prostatectomy performed in 2003 was 15,000 with figures
for radical nephrectomy and radical cystectomy 9000 and
4000, respectively.
     The report from Korea was made by Dr Kim, who began
by pointing out that prostate cancer is the sixth most common
cancer in Korean males with a prevalence rate of 7/100,000
population. Prostate cancer incidence increased by 211%
between 1995 and 2002. Surgery is the mainstay of treatment
for prostate cancer, especially radical prostatectomy and
open or laparoscopic and even robotic surgery, and many
patients receive radiotherapy. However, although many
treatment modalities are available for patients currently there
is no patient registration program specific for prostate cancer.
Therefore the UICC office in Asia represents a good chance
to begin international epidemiologic and prevention studies
in the region. There are two important ways in which Korean
researchers can collaborate with the UICC: first would be a
hospital-based clinical study or West Asian study. The second
is to capitalize on UICC's expertise to design a large
nationwide study.
     Following this, Dr Cheng speculated that the involvement
of UICC in Asia promises to bring the mission and purpose
of such groups as the Asian Trends in Prostate Cancer
Hormone Therapy society into much sharper focus,
especially as regards formulating an effective strategy to
lessen the burden of urologic cancer. UICC brings a
recognizable branding to the group, lending it a certain
legitimacy that everybody can acknowledge and perhaps
that will lead to better fundraising and more activities. The
main obstacles to the society's vision and mission include
technical dimensions such as mailing protocols, networking,
e-mail, and so on, but probably the biggest problem is that
Asian countries are at various different stages of
socioeconomic development and that makes it difficult to
collaborate. However, these obstacles are not
insurmountable. Researchers in each country need to make
a list of potential collaborations chiefly depending on what
is the purpose. It seems that a parallel effort to network all
cancer registries for all cancers by personal contact with
national registries is a good place to start. In particular, there
is at present a great window of opportunity for Asian
urologists that is fast closing: there is a large difference in
incidence rates of prostate cancer in various regions of Asia,
which provides us with an opportunity to study why that is
so before the difference diminishes altogether.
     The session ended with Dr Yang's presentation on the
situation in Taiwan, where the incidence and death rates of
prostate cancer have also increased rapidly in recent years.
Since 1982, all-site cancer has been the leading cause of
death in Taiwan. The National Health Department has been
working on a nationwide cancer registry and has built a
database of data on each cancer patient at every hospital
since 1979. The capital area, Taipei, has the highest
incidence rate of the disease with the Taichung area close
behind. Surprisingly, the area with the highest mortality does
not have the highest incidence, suggesting that treatment
may not be adequate in that region. Taiwan has its own
prostate cancer treatment guidelines but much of the data
used to prepare the guidelines were gathered in the USA
and Europe. Therefore if Asian countries could unite
together and share homegrown data it might be very useful
for disease control. Finally, the leading cancers in Taiwan
are hepatoma, stomach cancer, and breast cancer, so it is
always difficult to obtain funding for prostate cancer
research; international collaborations made possible by the
presence of UICC could improve that situation for
Taiwanese urologists.
II. Session 2: Detection Rate of Prostate Cancer
by Biopsy in Each Country chaired by Wun-
Jae Kim and Kesavan Esuvaranathan
1. Report from China presented by Dr Shujie Xie
Prostate cancer morbidity in China is growing fast. In
Beijing, the morbidity rate rose from 2.1 to 3.5/100,000
population between 1987 and 1995. In Shanghai over the
same period standard morbidity rose from 1.7 to 3.7/1000/
000 and reached 7.7/100,000 in 2000. Biopsy is the gold
standard for detecting prostate cancer. Indications for biopsy
are positive DRE and any PSA, elevated PSA level >10 ng/
mL with any free-to-total PSA ratio (f/t PSA) and PSA
density (PSAD), and PSA 4–10 ng/mL and abnormal f/t
PSA or PSAD. Furthermore, suspicious transrectal
ultrasonography or MRI is an indication for biopsy
irrespective of normal PSA parameters. Common strategies
for biopsy include rectal route and transperineal and
transrectal ultrasound-guided methods. Usually traditional
sextant biopsy is performed; also sextant biopsy plus
suspicious nodus and multiple (13) cores biopsy as
applicable.
     Factors well correlated with high tumor detection rate
include positive DRE, high PSA, older age, and high PSAD.
Gangzhi (2006) performed a study of the impact of different
prostate biopsy strategies on tumor detection rate, and found
that 8- and 10-core biopsy was associated with an overall
sensitivity of 94.8% and 97.4%, respectively, with no
significant difference observed versus 13 cores (P=1.25 and
0.5, respectively). However, sextant biopsy (apex/mid/base
or apex/mid/lateral base) was significantly (P<0.001)
inferior to multiple-core biopsy with a sensitivity of 85.7%.
On the other hand, sextant biopsy at apex/lateral mid region
was associated with a fairly high sensitivity of 90.9%
(P=0.008 vs 13 cores). In comparison with sextant biopsy,
>10-core prostate biopsy was not associated with more
complications such as hematuria, hemoproctia, fever,
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hemospermia, and dysuria although it caused more pain.
Indications for >10-cores biopsies include comparatively
large prostatic volume >40 mL, elevated PSA, negative
initial biopsy, and suspicious delitescence of prostate cancer.
Indications for repeated biopsy include PSA >10 ng/mL and
any f/t PSA or PSAD; for PSA 4–10 ng/mL if f/t PSA/PSAD
and DRE are normal but CT/MRI is positive or two
consecutive increases of PSA are observed over 3 months,
repeat biopsy is also performed.
     In conclusion, ultrasound-guided biopsy is common in
China; 13-cores biopsy is more accurate than other methods
but the detection rate in Chinese patients is similar to that
seen in other countries.
2. Report from Indonesia presented by Dr Rainy Umbas
Doctor Umbas presented data on first biopsy only
collected at Cipto Mangunkusumo Hospital over the last 11
years from 1995 to 2005 inclusively. At first, a 6–10-cores
biopsy is usually performed if the prostate volume is <60
mL, but >10 cores might be considered if the volume is
greater. Almost all biopsies are done on an outpatient basis.
Patients are given antibiotics such as ciprofloxacin for 3
days; all anticoagulants are stopped for ≥1 week, and
suppository painkiller might be used approximately 1 hour
before the procedure especially in the case of multiple-core
biopsy. Indications for biopsy are fairly standard: abnormal
DRE, PSA >10 ng/mL, or PSAD >0.15 if PSA level is 4–10
ng/mL. This latter indication is slightly different to the
preference in western countries wherein biopsy is usually
done when PSA is >4 ngmL; Indonesian doctors still use
PSAD 0.15 as cutoff level to do a biopsy.
     In the last 11 years, 455 patients were diagnosed with
prostate cancer at Dr Umbas' hospital; diagnosis was made
by biopsy in 68% of cases, TURP in 28.8%, and open surgery
in 3.3%. A total of 975 patients underwent first biopsy, and
the results were positive in 284 cases. Median PSA was 63.9
ng/mL in patients with positive biopsy and 15.5 ng/mL in
negative cases. Interestingly, 3.5% of positive cases had PSA
<4 ng/mL. Furthermore, among 691 patients with a negative
biopsy 515 (74.5%) had PSA >10 ng/mL, underlining the
notion that high PSA does not always guarantee the presence
of cancer. The sensitivity of PSA is quite good but physical
examination has superior specificity: if one can feel the
tumor, we can be almost sure to find it. Indeed, the positive
predictor value (PPV) for DRE is 92% whereas that for PSA
using a cutoff of >10 ng/mL is only 25.5%.
     Next, Dr Umbas looked at patients with normal DRE
(n=703) and observed that <10%, 63 patients, gave a positive
biopsy. Median PSA in these patients was slightly higher
than that in the negative biopsy group (21.6 vs 16.3 ng/mL,
respectively). These results suggest that the specificity is
very low and the PPV of PSA >10 ng/mL in normal DRE
patients is <10%. In patients with abnormal DRE, on the
other hand, of a total of 272 cases 221 went on to give a
positive biopsy. Nearly all of the patients with abnormal
DRE had PSA >10 ng/mL, and the specificity and PPV of
PSA >10 ng/mL was calculated as 100%.
     In conclusion, positive biopsy rate in patients with normal
DRE findings is quite low but in those with abnormal DRE
the rate increases to 80%. The overall average positive
biopsy rate is approximately 29–30%, and two thirds of
prostate cancer patients are diagnosed by TRUS biopsy.
Individuals with abnormal DRE and PSA >10 ng/mL are
by far the most likely to be biopsy positive.
3. Report from Japan presented by Dr Shiro Hinotsu
Doctor Hinotsu presented the results of the first survey
of JUA registration system data published in 2005 (JUA
2005). This database includes 4529 prostate cancer patients
from 173 institutes who were diagnosed in 2000. Tumor
stage of the patients and imaging methodology used are
shown in Figure 3. TRUS was used in approximately 80%
of cases, with two thirds of patients undergoing CT and
>40% MRI and almost three-quarters a bone scan. Just over
half of the patients had a 6-core biopsy; the proportion of
Japanese patients undergoing >6-core biopsy has probably
grown since the time these data were obtained. Among
patients who underwent biopsy at University of Tsukuba
between 1997 and 2004 <18% of those with <4 ng/mL were
positive whereas a positive diagnosis of prostate cancer was
obtained in 32% and 55% of those with PSA 4–10 and >10
ng/mL, respectively. Therefore higher PSA was associated
with higher detection rate in biopsy. These results are similar
to data obtained in the USA in 1993 (Haas et al, 1993).
Recently in Japan, however, it has been shown at one
hospital that the positive rate of biopsy in patients with PSA
2–4 and 4–10 ng/mL was the same (both 23.6%); hence it
might be advisable to lower the cutoff value for indication
to perform biopsy in future.
     Mass screening data on 197,682 Japanese men in Gunma
prefecture during the period 1989–99 show an overall
detection rate of 0.86%. Biopsy detection rate increased
according to age with about 10% positive rate in men aged
50–54 years rising to >45% in the 75–79- and >80-year age
groups; total biopsy positive rate was 34.0%. Similar results
were obtained in Ibaraki prefecture (Ito et al, 2000).The
first JUA treatment guideline for prostate cancer was
published in May 2006. Biopsy should be performed when
prostate cancer is suspected because of abnormal DRE, PSA,
or imaging. PSA cutoff level is 4.0 ng/mL; there seems not
sufficient evidence to lower this value at present. Age-
adapted cutoff level is also controversial. Recommended
number of biopsy cores is standard 6 + 2 or 4.
     In summary, most Japanese physicians currently accept
PSA cutoff level to perform biopsy as 4.0 ng/mL; biopsy is
usually performed by TRUS-guided method, and the
Figure 3. Tumor Stage for 4,529 Japanese Patients
Diagnosed with Prostate Cancer in 173 Institutes  in 2000
According to the JUA Registry
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detection rate according to PSA <4, 4–10, and >10 ng/mL
is 20–25%, 25–30%, and >50%, respectively. The detection
rate increases according to age in mass screening.
4. Report from Korea presented by Dr Jae Mann Song
Korean data are slightly different to those obtained in
other countries. For example, in Korean men aged >65 years
prostate cancer is the fifth most common neoplasm and sixth
in all age groups. In Korea onset of prostate cancer most
commonly occurs in men aged in their 60s (41% of cases)
followed by 70s (37%). Prostate cancer is also the most
steeply increasing tumor observed in male patients, with a
211% increase over the period 1995–2002 followed by colon
cancer with a 184% increase. By comparison, incidence rates
of cancers of the lung, urinary bladder, liver, and stomach
have remained relatively stable over the same period.
     Detection rates according to PSA level in a cohort of
3555 Korean men with abnormal DRE who were enrolled
in a multicenter prospective study from October 2004 to
January 2006 are shown in Table 2. All patients underwent
TRUS-guided biopsy and data on clinical parameters and
pathologic features were evaluated at the Korean National
Cancer Institute. In men with PSA <2.5 ng/mL the detection
rate was 10%. Interestingly in those with PSA 4–9.9 ng/mL
the rate was only 18.7%, which was slightly lower than that
observed in men whose PSA was 2.5–3.9 ng/mL (19.2%).
In men who had a PSA value PSA >20 ng/mL cancer was
detected 77%. Total detection rate was 30%.Percent free
PSA was found a very useful parameter when considering
whether to do biopsy especially in elderly patients aged >65
years. In these individuals, free PSA <10% was associated
with a detection rate of 48%; however, in younger patients
aged <65 years the percent free PSA was not so useful.
     Detection rates according to laterally deviated, directed
sextant biopsy, 10-core biopsy, and 12-core biopsy were
very similar across the range of PSA levels; total detection
rates in each biopsy group were 35.4%, 26.6%, and 32.2%,
respectively. Comparing sextant versus 12-core biopsy, a
significant (P<0.05) difference of detection rate was noted
only in the PSA range 2.5–3.9 mg/mL. Similar detection
rates using sextant or 12-core biopsy were also noted when
patients were subdivided according to prostate volume, with
both biopsy numbers giving lower detection rates as volume
increased (overall detection rate with prostate volumes <30,
30–49, and >50 mL: 35.3, 34.4, and 22.7%, respectively).
     Detection rates steadily increased with age: in men aged
<50, 50–59, 60–69, 70–79, and >80 years the rates were
8.3%, 19.4%, 32.7%, 38.7%, and 56%, respectively.
Detection rate was also higher if cancer was suspected by
DRE: in those with cancer suspicious and normal DRE
findings the rates were 584/1126 (51.9%) and 422/2123
(19.9%), respectively.
     In conclusion, the detection rate of first cancer in Korean
men with PSA 2.5–3.9 ng/mL is quite similar to that for
men with PSA 4–<10 ng/mL (approximately 20% in both
groups). The detection rate of first cancer in Korean men
with PSA 4–9.9 ng/mL is lower than that observed in
western patients, in whom the rate is reported as 25–30%.
Percentage free PSA can be used as guide for biopsy
especially in elderly men (aged >65 years) with PSA 2.5–
9.9 ng/mL. There is no significant improvement of prostate
cancer detection rate using extended biopsy compared with
sextant biopsy in Korean men.
5. Report from Singapore presented by Dr Christopher
Cheng
Since there has been no recent autopsy series using
modern Epstein criteria of the Gleason score conducted in
Asia the actual prevalence of prostate cancer is unknown.
However, ever-increasing numbers of papers by Asian
urologists and the data presented from each country at this
meeting suggest that we are all talking the same language.
Eventually, it is assumed that detection rates will be the
same among the various countries. Nevertheless, in Asia
we are seeing a dramatic rise in the incidence of prostate
cancer. However, this rise has not been seen in every country
possibly because of the way it is reported, differences of
population demographics, number of urologists, and so on.
Although mass population screening is not recommended,
the population needs to know what is our stance with regard
to prostate cancer detection.
     In light of this, Professor Cheng presented data on
Prostate Awareness Week (PAW) 2004 Singapore. PAW is
a voluntary effort, not screening, and reaches a different
population to that encountered in the urology office. The
first analysis of 3,651 Singaporean males with median age
62 years showed that PSA steadily increased by age range;
the mean for men aged 50–60 years was 1.2 ng/mL rising
to 2.05 ng/mL in men aged 60–70 years and 2.66 ng/mL in
men aged 70–80 years. In PAW 2004, 252 men (7.4%) had
elevated PSA (>4.0 ng/mL). Of these, 84% had PSA 4–10
ng/mL and 12% 10–20 ng/mL. The entire cohort with
elevated PSA was invited to undergo biopsy, and 168 (60%)
underwent the procedure. A total of 43 were revealed to
have cancer. Of the cancers detected, the majority were
Gleason 6, a few Gleason 7, and very few Gleason ≤5. Most
had clinical stage T1 disease. Overall, the cancer detection
rate during PAW 2004 was 1.2%.
     Professor Cheng also analyzed the repeat biopsy audit.
Based on the first biopsy histology on a consensus basis
men were asked to undergo second, third, and fourth biopsy
over 6–12 months. In the first biopsy the detection rate was
27.6%, second biopsy 18%, and third 33%. A few patients
eventually had TURP that revealed incidental low-grade
cancer. Of the 95 repeat biopsies cancer was detected in
13.7%, mostly on the second biopsy and very few on the
third and fourth.
Table 2. Detection Rates According to Serum PSA in
3,555 Korean Men*
     PSA level (ng/mL)   Detection rate, n (%)
<2.5 16/154 (10.4)
2.5–3.9 51/266 (19.2)
4.0–9.9 354/1892 (18.7)
10–19.9 213/645 (33.0)
>20 463/598 (77.4)
Total 1097/3555 (30.9
*Patients enrolled at 26 Korean hospitals evaluated by TRUS-
guided biopsy
Hideyuki Akaza et al
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6. Report from Taiwan presented by Dr Chi-Rei Yang
Widespread screening is not conducted in Taiwan.
However, although hospital-based health check-ups are not
available, community-based screening of asymptomatic
patients such as PSA testing in men aged >60 years does
occur. In community-based screening conducted at various
locations in Taiwan, people with abnormal PSA (>4 ng/
mL) ranged from 4.4% to 16.1%; the average was 11% in
that setting. In hospitals abnormal PSA is observed in 6%.
Of 306 men with abnormal PSA as detected by community-
based screening, finally only 91 received biopsy and this
was positive in 26%. Therefore the overall detection rate
of community-based screening in Taiwan was 26/2716
(1%).
     In a study of 785 Taiwanese men who underwent TRUS-
guided sextant biopsies the prostate cancer detection rate
in those with PSA 4–10 and 10.01–25 was 63/533 (11.8%)
and 79/252 (31.3%), respectively; overall detection rate was
17.9%.
     In another study conducted in 2003 no difference was
observed in detection rate according to whether 6–8 biopsy
cores or 10–14 cores were analyzed irrespective of PSA. In
men whose PSA was 3.5–10 and 10–20 ng/mL the detection
rate for 6–8 and 10–14 cores was respectively 32/326 (9.8%)
and 36/226 (15.9%) (P=0.040), respectively, and 22/122
(18.0%) and 55/302 (18.2%), respectively (P=0.319).
     When men were stratified according to prostate volume
30, 30–50, and >50 mL, higher detection rates were noted
in those undergoing 10–14-core biopsy than 6–8-core
biopsy, especially in men whose PSA was 10.1–20 ng/mL.
In men with prostate volume 30, 30–50, and >50 mL
detection rates for 6–8 and 10–14 cores were respectively
41.9% and 60%, 25% and 31.5%, and 5.3% and 16.2%,
respectively. Therefore in patients with large prostatic
volume more prostate cores should be done for early
diagnosis of prostate cancer.
III. Session 3: HRPC, Favorable Treatment
Modality in Each Country (chaired by Rainy
Umbas and Shujie Xie)
1. Report from China presented by Dr Shujie Xie
According to treatment guidelines for HRPC in China
it is necessary to maintain serum testosterone at castration
level. Available therapeutic options include cytotoxic and
Chinese traditional herbal medicines, which are widely
accepted among doctors and patients alike. Chemotherapy
is another popular choice of treatment for these patients.
Single-agent estramustine also can be given to Chinese
HRPC patients. Some doctors combine chemotherapy to
improve response rates, with measurable response observed
in 40–50% using this strategy. Prednisone 10 mg/day and
mitoxantrone 12 mg/m2 every 3 weeks is another available
modality but there is not very much evidence for its efficacy.
Radioisotopic drugs especially strontium 89 are commonly
used as painkiller for patients with bone metastases.
According to the guideline recommendations for cytotoxic
therapy against HRPC, if the PSA level is above 2 times
the previous reference level the increase should be
documented. When chemotherapy is indicated this should
be communicated to the patient. In some patients Chinese
doctors also use radionuclides, external beam radiotherapy,
and analgesics in the setting of bone metastasis. In patients
with metastatic disease treatment is challenging and a
standard approach is rare.
2. Report from Indonesia presented by Dr Doddy Soebadi
HRPC is very frustrating because often if a patient has
metastatic prostate cancer he becomes very dependent on
his doctor; such patients visit us every month and ask about
their PSA: if it is going down they are very happy, but when
the PSA stops going down or increases they become
worried—as does the doctor.
     In Indonesia there are no reliable nationwide
epidemiologic data, but in Surabaya between 1982 and 2002
the number of patients with prostate cancer increased 6 fold.
At Dr Soebadi's center among 40 patients with HRPC 70%
previously underwent orchiectomy, 15% had received LHRH
analog therapy, and the other 15% maximal androgen
blockade. Treatment policy at the center is to continue with
hormone therapy either with LHRH analog or offer referral
for an orchiectomy. The problem is that for LHRH analog
patients themselves have to bear the cost and the treatment
is very expensive. An alternative is to give the patient
chemotherapy; in this setting a lot of encouragement is
required for patients and their families because
chemotherapy is also costly and possible side effects must
be explained in addition to benefits and response rates. In
patients who are deteriorating palliative or symptomatic
control is needed. For bone metastases, if the patient can
afford it we give him zoledronic acid, maybe surgery for
pathologic fracture, or symptomatic control of pain with
radiotherapy. For anemia transfusions are given as needed.
Obstructive uropathy may be an indication for TURP or
stenting; steroids are often given for nerve compression, and
for other complaints such as nausea and vomiting good
nutrition possibly supplemented with megesterol and
supportive therapy is counseled to the patient and his family.
Chemotherapy is aimed at palliation of symptoms and
reducing PSA. Estramustine phosphate is recommended but
not available in Surabaya and the patient's family may have
to go to Jakarta or Singapore to obtain this agent. Medical
oncologists also give docetaxel with prednisone. In addition,
it is estimated that >50% of patients take traditional remedies
such as herbal preparations and shark's fin cartilage.
     In conclusion, in Indonesia guidelines for HRPC and
symptom control are needed. Also the role of cultural,
complementary, and alternative treatments merits deeper
investigation.
3. Report from Japan presented by Dr Michiyuki Usami
In Japan there are many hormonal treatment modalities
available for prostate cancer. Many patients receive
combined androgen blockade; LHRH agonist and
antiandrogen are also used. Orchiectomy alone is performed
in 5%. After relapse, for the castrated group antiandrogen is
added or LHRH monotherapy. It is important that
testosterone levels are monitored. If testosterone is well
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suppressed other antiandrogens may be added; if
testosterone is not suppressed castration or switching to
another agonist plus antiandrogen or antiandrogen plus
LHRH agonist may be indicated. At next failure
antiandrogen is changed to another antiandrogen.
     Second-line treatments for patients who fail androgen
ablation therapy include corticosteroids and chemotherapy
using estramustine phosphate, cyclophosphamide, or
docetaxel. However, the Japanese government does not
reimburse docetaxel. A few patients enter clinical trials of
experimental new agents. For palliation several drugs are
available such as zoledronic acid in patients with bone
metastasis.
4. Report from Korea presented by Dr Sung Joon Hong
Doctor Hong's presentation focused on prevailing
clinical trends in the management of HRPC in Korea. In
2004, the Korean Urological Oncology Society suggested
clinical guidelines on prostate cancer including HRPC
(Figure 4); the guideline is similar to internationally
suggested guidelines, so Dr Hong restricted his talk to
secondary hormone therapy, chemotherapy, and palliative
treatment in Korea.
     Presented was a case of a 60-year-old man with PSA
25.6 ng/mL who sought treatment in January 2001. He had
a Gleason score 7, and MRI, CT, and bone scan revealed
clinical stage cT4acN2cM1b. He took LHRH agonist
combined with bicalutamide; after 3 months his PSA
dropped to zero level and he continued therapy for almost
2 years till a slight increase was observed. Antiandrogen
was withdrawn and his PSA stabilized for nearly 6 months
then began to rise and at this time newly developed spinal
metastases were discovered. Estramustine was at first tried
and his PSA dropped. Radiation therapy was given to control
the bone pain. Eventually when the PSA became elevated
again dexamethasone was additionally given and PSA
dropped rapidly; subsequently docetaxel was given 6 times.
PSA re-elevated so docetaxel plus prednisolone combination
for 6 cycles was tried. PSA dropped immediately but not
for long and later became elevated again. This case includes
almost all of the up-to-date therapeutic modalities in Korea.
     Secondary hormonal therapy is usually given as single
drugs, but prednisolone and dexamethasone can be given
at first. Recently, Dr Hong uses high-dose bicalutamide
monotherapy. The Korean health insurance regulatory
agency has grouped chemotherapy into two classes:
protocols containing estramustine- and mitoxantrone-based
combinations on the one hand and docetaxel-based
combination therapy on the other. The first group is not
restricted as strictly as the second. After 3 cycles with
elevated PSA docetaxel-based combinations must be
stopped.
     In Korea the armamentarium against prostate cancer-
related bone pain includes anti-pain medications, external
radiotherapy, radiopharmaceuticals such as strontium 89,
and bisphosphonate.
5. Report from Singapore presented by Dr Kesavan
Esuvaranathan
In Singapore testosterone-deprivation therapy (TDT) is
indicated for the treatment of metastatic prostate cancer in
approximately 50% of cases, PSA relapse (>0.2 ng/mL)
following radical prostatectomy, and as primary therapy with
or without TURP in certain patients with locally advanced
disease. Furthermore, TDT is given with radiotherapy in
the neoadjuvant setting and as adjuvant therapy with or
without radiation against margin-positive prostate cancer
with persisting PSA.
     Forms of TDT include LHRH agonist (goserelin or
leuprolin) in 90% of cases, orchiectomy in 8%, bicalutamide
monotherapy (1%), and cyproterone acetate (1%). After
bone mineral density evaluation bisphosphonates may be
considered for patients with osteoporosis or bone metastases.
     The protocol for surveillance in Singaporean patients is
usually clinical review every 3 months or every 6 months
in elderly or infirm individuals.
     For HRPC the treatment algorithm is LHRH agonist with
serum testosterone monitoring. If the decision is not to
castrate, bicalutamide or flutamide may be added; if the
patient is to be castrated trial of antiandrogens should be
discussed and the medical oncologist consulted. When
antiandrogen is given as monotherapy LHRH agonist may
be added. When this treatment fails, antiandrogen is
withdrawn; if the patient is on flutamide, he may be switched
Figure 4. Guidelines for HRPC Management in Korea )published by the Korean Oncological Society, 2004)
Hideyuki Akaza et al
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to bicalutamide. Finally, chemotherapy containing
estramustine or new agents may be considered.
6. Report from Taiwan presented by Dr Shu-Jen Chang
In Taiwan primary hormonal therapeutic options for
metastatic prostate cancer include orchiectomy, flutamide
or cyproterone (Androcur®), LHRH agonist, and combined
androgen blockade.
     In patients who progress flutamide or bicalutamide
(Casodex®) may be added or orchiectomy or LHRH offered.
When these strategies fail flutamide should be withdrawn
and diethylstilbestrol (DES) tried as third line of hormonal
therapy. DES has cytotoxic effects and if given at 1–3 mg/
day can elicit 30–40% response rates including PSA
reduction and improvement of physical condition. The effect
normally lasts 3–6 months and in some patients ≤2 years.
DES is cheap and very applicable to oriental patients who
experience less cardiovascular accidents on this agent than
western patients. About 5% of patients treated with DES
have very severe adverse events such as thrombosis and
this can be countered by warfarin. After DES there is no
more hormone therapeutic option to control the cancer and
on progression chemotherapy should be used for HRPC. In
Taiwan etoposide, mitoxantrone plus prednisolone, and
paclitaxel are available; estramustine has been withdrawn
from the Taiwanese market for 1 year. About 30% of patients
respond to etoposide. Treatment can be done at home and
patients are advised to visit their clinics for follow-up. This
is very easy for older patients in particular; prices are good
and side effects tolerable on most occasions. Patients who
experience difficulty in swallowing the large etoposide
capsule can instead take mitoxantrone and prednisolone,
which is safe and achieves a similar response rate that lasts
approximately 6 months. Recently, docetaxel was approved
in Taiwan. Patients who do not respond to the more tolerable
chemotherapeutic regimens may be switched to receive
docetaxel. This treatment should be given by medical
oncologist since docetaxel is more toxic than other
chemotherapy agents and side effects such as leukopenia
make the patient very sick and weak.
     Radiation therapy is given as palliation for bone pain
and to keep the patient away from morphine. Patients on
morphine need a lot of care and normally there is no person
available to look after them round the clock.
IV. Summary and Closing Remarks
At the end of session 3 chairperson Dr Umbas rounded
up the proceedings by reminding participants that the first
important strategy is to ensure that patients have a castration
level of testosterone. Second, for patients who require
chemotherapy it is best to sit together with the medical
oncologist and radiotherapist and concoct a workable
protocol so that each patient with similar clinical features
receives the same treatment; then at the end of the day the
results can be properly evaluated, which is also important.
     Following this, conference co-chair Seiji Naito (Japan)
in his closing remarks thanked the participants and sponsor
AstraZeneca and looked forward to a bountiful relationship
with UICC in Asia Pacific. The schedule for the next
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